Skip to main content
Evidence Snapshot

Mitogen-activated protein kinase 8

CHEMBL2276 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:20:30Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2276
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase 8 as ChEMBL target CHEMBL2276, mapped to UniProt P45983. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase 8
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2276
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P45983
Mitogen-activated protein kinase 8
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Mitogen-activated protein kinase 8 matters

As of 2026-09-13

Mitogen-activated protein kinase 8 is reviewed as Mitogen-activated protein kinase 8 (UniProt P45983); Mitogen-activated protein kinase 8 shows clinical signal disease relevance led by idiopathic pulmonary fibrosis. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 17 approved drugs, 4411 compounds, and 864 assays, with lead potency reaching pChEMBL 10.5.

Disease context
idiopathic pulmonary fibrosis

Mitogen-activated protein kinase 8 shows clinical signal disease relevance led by idiopathic pulmonary fibrosis. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include TANZISERTIB.

Start review with idiopathic pulmonary fibrosis because it currently carries clinical signal support. Linked drugs include TANZISERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 17 approved drugs, 4411 compounds, and 864 assays for this target. The dominant activity type is IC50. CHEMBL4546504 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL4546504 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
17 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Mitogen-activated protein kinase 8 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P45983, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why idiopathic pulmonary fibrosis is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4411
Total Compounds
864
Total Assays
17
Approved Drugs
IC50: 2259.0, KI: 973.0, EC50: 12.0, KD: 449.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4546504
 10.5 IC50 —
No preferred name
CHEMBL2392833
 9.8 Kd —
No preferred name
CHEMBL3220502
 9.6 IC50 —
No preferred name
CHEMBL1822313
 9.2 IC50 —
No preferred name
CHEMBL2425628
 9.1 Kd —

Approved Drugs

Structure Compound First Approval
MOMELOTINIB
CHEMBL1078178
 2023
FEDRATINIB
CHEMBL1287853
 2019
GILTERITINIB
CHEMBL3301622
 2018
NINTEDANIB
CHEMBL502835
 2014
PAZOPANIB
CHEMBL477772
 2009
NILOTINIB
CHEMBL255863
 2007
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:20:30Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2276